NAYA Biosciences has exhibited an explosive year-over-year sales growth of 390.03% and a quarterly growth of 481.38%, indicating strong business expansion. However, the stock experienced significant declines over the quarter (-61.81%) and has a highly negative return on equity (-14358.50%) and ROI (-140.49%). The market cap is low at $1.47M, accompanied by high volatility and a substantial debt-to-equity ratio of 3.96, pointing to high risk.